Between 2019 and 2020, illicitly manufactured fentanyl-related overdose deaths increased substantially in western, southern, and midwestern states, CDC reported.

FDA said it is temporarily halting its risk evaluation and mitigation strategy (REMS) program for clozapine, a treatment for schizophrenia.

The Pharmacy Technician Certification Board (PTCB) announced the launch of a new certificate in MTM for pharmacy technicians.

This year has seen the approval of 2 new biosimilar drugs, including the first biosimilar to earn FDA’s “interchangeable” designation. Byooviz (ranibizumab-nuna) is biosimilar to Lucentis (ranibizumab), a drug for neovascular (wet) age-related macular degeneration (nAMD). Semglee (insulin glargine-yfgn), the first such drug to earn the “interchangeable” distinction, is biosimilar to Lantus (insulin glargine) for diabetes.

New data from CDC’s Autism and Developmental Disabilities Monitoring (ADDM) network show that 2.3% of children aged 8 years in 11 communities across the United States had an autism diagnosis in 2018.